搜索到 1000 条关于 무료인터넷바카라 Wt77.TOP 코드 6520 카지노 보증사이트 에볼루션 작업팀 무료 바카라 게임 iq 的文章
-
2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)
时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd会议简介
According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..
IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.
5 Reasons To Attend - Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
- Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
- The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
- Showcasing unique case studies from leading Asian and international biosimilar companies
- Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success
Industry Gurus / Speakers Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals Past Attendees Include Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)Registration FEES per delegate Early Bird Rate
Register & Pay before 11 March 2011Special Rate
Register & Pay before 15 April 2011Normal Rate
Register & Pay after 15 April 2011Group Rate
Group of 3 or more? US$ / CNYUS$ / CNYUS$ / CNYUS$ / CNY4 day package
(Conf + Pre & Post Workshops)2,495 /
16,6002,695 /
17,9502,895 /
19,5002,175 /
14,6503.5 day package (Conf + Workshop C & A or B ) 2,295 /
15,5002,495 /
16,6002,695 /
17,9502,025 /
13,5003 day package (Conf + Workshop A & B or C) 1,995 /
13,5002,195 /
14,6002,395 /
15,9501,795 /
12,0002.5 day package (Conf + Workshop A or B) 1,795 /
12,0001,995 /
13,5002,195 /
14,6001,695 /
10,9502 day package
(Conf only)1,495 /
9,9501,695 /
11,3001,895 /
12,6001,495 /
9,950PAYMENT TERMS
Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.Payments by Singapore Dollars (S$)
Payments by RMB (CNY)- Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
- Payment by telegraphic transfer in S$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 147-059513-001 (SGD)
The Hongkong and Shanghai Banking Corporation Limited
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232 - Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
- Payment by telegraphic transfer in CNY must be made to:
A/C Name:
A/C No.: 720-031103-001
Beneficiary Bank:
Bank Address: No. 1000 Lujiazui Rind Road,
Pudong, Shanghai 200120, P.R. China
Bank Swift Code: HSBCCNSH
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.
DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.联系方式电话:+65 650 82401
-
-
2021.08.02 2021 年 6 月最受欢迎的品牌案例
本期「TOP list ·月度案例评选」是基于 6 月在丁香园医院汇平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10排名医院
-
-
2020.06.30 2020 年 6 月最受欢迎的品牌案例
本期「TOP list ·月度案例评选」是基于 6 月在丁香园 医院汇 平台上发布的文章,根据阅读量及点赞量呈现医疗行业「最受欢迎的品牌案例」TOP 10。医院汇努力为医疗行业从业者打造优秀品牌案例库,供行业宣传人士参考学习,也是众医院打造品牌曝光的重要营地。新闻资讯 TOP 10
-
-
2015.11.14 丁香园力荐 最受医生欢迎的 20 本必备好书
「借花献佛」,和大家分享下推荐最多的 10 本 「案头必备」和 10 本 「床头必备」好书。一、案头必备TOP 1. 实用内科学推荐理由:中国医学界唯一一部畅销...出版一次,已出至第14版,可及时反映国内外进展,是内科领域各级学科医师的 「不二宝典」。TOP 2. 坎贝尔骨科手术学推荐理由:国际权威骨科经典著作,内含众多
-
-
2013.12.27 2013年5大重磅新药
2013年岁末已至,回首这一年,一批「重磅炸弹」级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top1 默克...晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2 糖尿病治疗的新突破强生和Evotec公司共同开发
-
-
2013.12.25 盘点2013年改变世界的5大重磅新药
2013年岁末已至,回首这一年,一批"重磅炸弹"级新药的诞生,使得生物制药成为全球医药领域的一个焦点。Top...积极的数据。制药巨头正准备将晚期黑色素瘤临床试验和非小细胞肺癌试验结果提交给监管机构。Top2:糖尿病治疗的新突破强生和Evotec公司
-
-
2020.10.23 学术成果 | JSH 2020 :陆道培分子医学室硕果累累
医院分子医学室张阳医师墙报展示 2「Evaluation of Otsuka WT1 real-time PCR kit for quantitative detection of WT1 mRNA expression」马小丽检验师带来的墙报内容为探讨日本大冢制药生产的商品化 WT
-
2012.09.19 2010 第五届国际基因组学大会(ICG-V)
, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster
-
-
2016.08.09 七夕节:话一话古代十大奇葩避孕方式
CRACKED 网站为大家来盘点了历史上奇葩十大避孕措施,看完之后你会觉得没有什么不可能,妇产君反正已经看到下颌脱臼了。Top 10 黄鼠狼睾丸欧洲正处于「黑暗时代」时期...吧。Top 9 鳄鱼便便创造出了金字塔、木乃伊的古埃及人,在避孕这件事上可以说是煞费苦心,想法也算得上简单粗暴。想要避免怀孕?只要用一些东西堵住不让精子进入
-
2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)
。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱
-
2012.09.19 2012 中国医疗器械高峰论坛
trials and regulatory affairs A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
-
2022.04.15 停招国防七子及北邮学生?微软登上热搜!美国「制裁清单」影响开始深入校园
包括国防七子,还包括所有实体清单大学。所谓「实体清单」,是美国商务部公布的一份对华77个实体及个人“制裁”清单。是美国为维护其国家安全...和本土民企。同样,北理工2021届毕业生重点就业单位也是军工国企和本土民企,甚至乎,TOP30就业单位中没有一家外企。
-
-
2020.10.13 【重磅揭晓】2020 年度中国医院公益风云榜
轮数据评鉴,经认真的讨论审议,现将 2020 年度中国医院公益风云榜推选情况公布如下:一、年度公益医院风云榜 TOP100 强(依据得分排序)1 佛山市中医院...76 北京清华长庚医院77 西南医科大学附属中医医院78 吉林大学第二医院79 蚌埠医学院第二附属医院80 东莞市妇幼保健院81 济宁医学院附属医院
-
-
2018.03.27 甲氨蝶呤不只是异位妊娠那么简单,看看中外指南怎么说
,2018,131(2):e65-e77.[2] Diagnosis and Management of Ectopic Pregnancy: Green-top
-
-
2016.09.10 Medscape:美国超 90% 医生使用电子病历
而改用系统的。图 16 电子病历对病人隐私的威胁关于电子病历可能导致病人隐私泄露的问题,2012 年 77% 的医生表示他们并不担忧。然而,今年只有 8% 的... Report 2016: Physicians Rate Top EHRs
-
-
2016.07.16 多角度 PK 审视全球在研新药:未来由谁主导?
个; 糖皮质激素受体仍然位居第二位; 肿瘤坏死因子、前列腺素氧化环化酶 2(COX-2)、Her-2 则分别位列第三至第五位。在 TOP 10 药物靶标蛋白中...研发行业创新程度的一个重要指标。在过去的 12 个月中,该行业新增靶标蛋白数量为 113 个,较去年的数据 (77个)有显著提高。2013-2015 年的靶标